Mainboard-listed C & O Pharmaceutical Technology (Holdings) says it has secured a sales contract which will bring in revenue of RMB32 million ($6.4 million) in three years.

This involves the exclusive distribution of C&O-developed Cidofovir Dihydrate in the US.

C & O Pharmaceutical says the distributor will be responsible to seek United States Food and Drug Administration approval of C&O’s Cidofovir Dihydrate.

Cidofovir Dihydrate is an active pharmaceutical ingredient (API) for the production of Cidofovir, which is widely used in the United States.

Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with weak immune defences caused by various diseases including Human Immunodeficiency Virus (HIV). About 5% of HIV patients develop CMV retinitis.